Second infusion of CAR-T based on ctDNA for large B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a second infusion of a CAR-T cell therapy called Axi-cel, given early based on a blood test (ctDNA), can help people with relapsed or hard-to-treat large B-cell lymphoma. If you had a partial response or your ctDNA stayed positive after the first dose, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of large B-cell lymphoma that has come back or not responded to treatment.
- You have had at least one prior treatment that didn't work or stopped working.
- You have at least one tumor that can be measured on a scan.
- Your heart, liver, kidneys, and blood counts are good enough for the treatment.
- You had a first infusion of Axi-cel within the last 60 days, and your ctDNA is still positive or you only had a partial response on a PET/CT scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
This early-stage trial tests an automated version of axicabtagene ciloleucel (a CAR-T cell therapy) for large B-cell lymphoma that has come back or stopped responding to initial chemotherapy. CAR-T therapy uses your own immune cells, modified in a lab to fight cancer cells.
This trial tests whether a type of immunotherapy called axicabtagene ciloleucel (a CAR T-cell therapy) can improve outcomes when given right after initial treatment for high-risk large B-cell lymphoma. It is for people who have not yet started treatment.
This trial tests whether the CAR-T cell therapy axicabtagene ciloleucel (a type of immunotherapy made from your own immune cells) can be effective as a first treatment for people with aggressive large B-cell lymphoma that hasn't responded well after two rounds of chemoimmunotherapy. It's designed for patients with high-risk features who might need a stronger approach early on.
This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Hear when a new Relapsed/Refractory Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.